Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu | (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats:
- Alabama Drug Discovery Alliance
- Biochemistry and Molecular Genetics
- Biomatrix Engineering and Regenerative Medicine
- Cell biology
- Center for Biophysical Sciences and Engineering
- CCTS
- Center for Metabolic Bone Disease
- Microbiology
- Neurobiology
- Comprehensive Neuroscience Center
- Pathology, research shared with MS2
- Pharmacology and Toxicology
- Physiology and Biophysics
- UAB Research Foundation/IIE
- Research Administration
Tuscher is one of what the foundation calls “150 of the world’s most promising young scientists” doing groundbreaking neurobiological research.
One participant said, “It seems like we’ve done 10 years of work in seven months!”
This study used powerful genomic tools and supercomputers to analyze massive amounts of genetic data and identify individual strains within single species of the gut microbiome present during an infant’s first 6 years of life.
Layers of tannic acid and another biopolymer delay allograft and autoimmune-mediated rejection in mouse models of Type 1 diabetes.
A monoclonal antibody is being developed by Aridis Pharmaceuticals as an inhaled, self-administered treatment for non-hospitalized patients who are suffering from mild to moderate COVID-19.
The vaccine candidate Altimmune’s AdCOVID potently stimulated neutralizing antibody and T cell responses, as well as mucosal immunity in the respiratory tract.
Precision disease modeling involves creation of patient-specific disease models that mimic the molecular character of a condition present in a patient, enabling more precise diagnoses and treatments.
This avenue of basic research will aid understanding of neurodevelopmental disorders in humans.
The exosomes were secreted by cardiac cells derived from human induced pluripotent stem cells. These non-living exosomes may be an easier form of regenerative treatment than living cells.
These molecular insights may foster effective therapies using existing drugs for patients with COVID-19.